Mega-Mergers: Largest Recent M&A Transactions
By The Online Investor Staff, updated Thu., Jan. 28, 3:50 AM
Slide #1. BridgeBio Pharma, Inc. — Eidos Therapeutics, Inc.
Acquirer: |
BridgeBio Pharma, Inc. (BBIO) |
Acquiree: |
Eidos Therapeutics, Inc. (EIDX) |
Details: |
BridgeBio Pharma, Inc. ("BridgeBio") (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. ("Eidos") (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders. |
BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipelines include: BBP-265/AG10, an oral small molecule TTR, stabilizer, for the treatment of TTR amyloidosis; BBP-831/Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical AAV, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia; and BBP-454, a preclinical development program for the treatment of KRAS-driven cancers.
BBIO SEC Filing Email Alerts Service
Open the BBIO Page at The Online Investor »
BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipelines include: BBP-265/AG10, an oral small molecule TTR, stabilizer, for the treatment of TTR amyloidosis; BBP-831/Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical AAV, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia; and BBP-454, a preclinical development program for the treatment of KRAS-driven cancers.
BBIO SEC Filing Email Alerts Service
Open the EIDX Page at The Online Investor »
Company Name: |
BridgeBio Pharma Inc |
Website: |
www.bridgebio.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding BBIO: |
18 |
Total Market Value Held by ETFs: |
$562.01M |
Total Market Capitalization: |
$8.06B |
% of Market Cap. Held by ETFs: |
6.97% |
|
Company Name: |
Eidos Therapeutics Inc |
Website: |
www.eidostx.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding EIDX: |
22 |
Total Market Value Held by ETFs: |
$191.93M |
Total Market Capitalization: |
$4.97B |
% of Market Cap. Held by ETFs: |
3.86% |
|

Quotes delayed 20 minutes
 |
